

**BAKER BOTTS LLP.**Atty. Docket No. 31920-PCT-USA (072900.0107)  
PATENT**CLAIM AMENDMENTS**

Please amend the claims as follows:

1-8. (Cancelled).

2 ~~9~~. (Currently amended): The method of claim 7 <sup>1</sup>/~~21~~ wherein the human  $\alpha$ -interferon is obtained from a lymphoblastoid cell culture.

10. (Cancelled).

3 ~~11~~. (Currently amended): The method of claim 7 <sup>1</sup>/~~21~~ wherein the human  $\alpha$ -interferon is obtained from lymphocyte cells.

12. (Cancelled).

4 ~~13~~. (Currently amended): The method of claim 7 <sup>1</sup>/~~21~~ wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

14. (Cancelled).

5 ~~15~~. (Original): The method of claim <sup>2</sup>/~~9~~ wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

16. (Cancelled).

6 ~~17~~. (Original): The method of claim <sup>3</sup>/~~11~~ wherein the formulation is administered in a single dosage unit having a volume of approximately 1 milliliter.

18-20. (Cancelled).

1 ~~21~~. (Currently amended): A method of treating a subject human having type C viral hepatitis comprising administering to the subject human a daily dose of a liquid <sup>formulation</sup>

NY02:479369.1

**BAKER BOTTS** LLP.Atty. Docket No. 31920-PCT-USA (072900.0107)  
PATENT

of human  $\alpha$ -interferon, wherein the daily dose is administered by a peroral route, and  
wherein the daily dose is between 100 and 500 IU.

NY02:479369.1